Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00455494 · ClinicalTrials.gov registry record · Phase 1
Food-Effect Bioavailability Study of AQ-13, a Candidate Antimalarial
A Phase 1 study of Malaria, sponsored by Tulane University Health Sciences Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT00455494: Completed Phase 1 study of Malaria, sponsored by Tulane University Health Sciences Center.
NCT00455494 is a Phase 1 study of Malaria that has completed, run by Tulane University Health Sciences Center. The registered enrollment target is 14 participants, below the 258-participant average among 27 other Malaria trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00455494, a Phase 1 study of Malaria, has completed, sponsored by Tulane University Health Sciences Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to test the safety of a 2100 mg dose of AQ-13, a new candidate antimalarial active against drug-resistant P. falciparum infection, and to determine the effect of a standard fatty meal on the absorption of the drug from the gut and its blood levels.
Conditions Studied
Interventions
- DRUG AQ-13
Study Locations (1)
Louisiana
- Tulane-LSU General Clinical Research Center - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2005-01 |
| Est. Completion | 2006-12 |
| Phase | Phase 1 |
What the finished NCT00455494 record still lists
NCT00455494 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 258-participant average among 27 other Malaria trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Malaria appearing as the primary indexed condition, and to 1 intervention - of which AQ-13 is the first listed.
NCT00455494 reports a single indexed study location in Louisiana.
Frequently Asked Questions
What is clinical trial NCT00455494 about?
NCT00455494 is a clinical study titled "Food-Effect Bioavailability Study of AQ-13, a Candidate Antimalarial". The purpose of this study is to test the safety of a 2100 mg dose of AQ-13, a new candidate antimalarial active against drug-resistant P. falciparum infection, and to determine the effect of a standard fatty meal on the absorption of the drug from the gut and its blood levels.
What is the current status of trial NCT00455494?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2005-01. Estimated completion is 2006-12.
What conditions does trial NCT00455494 study?
This clinical trial studies the following conditions: Malaria.
What interventions are being tested in trial NCT00455494?
The interventions under investigation include: AQ-13 (DRUG).
Who is sponsoring clinical trial NCT00455494?
This trial is sponsored by Tulane University Health Sciences Center, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00455494 being conducted?
This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malaria
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00455494's enrollment target sits among peer trials
14 27th of 27 higher than 1 of 27 other Malaria trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Malaria trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Oral E1018 in Healthy Adult Participants
RECRUITING · Phase 1
-
Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium Vivax Challenge Agent and Evaluate Transmission in Mosquito Feeding Assays
RECRUITING · Phase 1
-
First-in-Human PfSPZ-LARC2 Vaccination/CHMI
ACTIVE NOT RECRUITING · Phase 1
-
A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria
ACTIVE NOT RECRUITING · Phase 1
-
Trial to Evaluate CIS43LS in Healthy Adults
COMPLETED · Phase 1
-
Blood-Stage Plasmodium Vivax Cell Bank
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia